IDH1 and glioblastoma: According to the cIMPACT-NOW criteria (4), the molecular diagnosis of glioblastomas, IDH-wild type (GBMs, IDHwt) is essentially based on the presence of at least one of the following alterations in the context of an adult diffuse astrocytic neoplasm, IDH-wt: i) combined 7p gain and 10q loss, ii) epidermal growth factor receptor (EGFR) amplification, and iii) telomerase reverse transcriptase (TERT) promoter mutation (5, 6).